Expert Directory

Showing results 1 – 7 of 7

Roy Herbst, MD, PhD

Ensign Professor; Professor; Chief

Yale Cancer Center

Lung Cancer, Nsclc, Clinical Trials For Cancer, Yale Cancer Center, Immunotherapy

Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst’s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led.

After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts.

Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer.

Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer.

He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). Dr. Herbst was awarded the 2010 Waun Ki Hong Award for Excellence in Team Science by the Division of Cancer Medicine, UT-MDACC. The Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research was bestowed upon him by Dana-Farber/Brigham and Women’s Cancer Center in 2014. That same year, the Bonnie Addario Foundation honored him with the Annual Addario Lectureship Award and the Bonnie J. Addario Excellence in Collaboration and Innovation Award. In 2015, the Clinical Research Forum presented his project “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients” its top Clinical Research Achievement Award in the United States for 2015. For his lifetime achievement in scientific contributions to thoracic cancer research, Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. His work has been funded by ASCO, AACR, the United States Department of Defense, and the National Cancer Institute. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant.

EDUCATION & TRAINING
MMS	Harvard University, Clinical Translational Research (1997)
MD	Cornell University Medical College (1991)
PhD	Rockefeller University (1990)
BS	Yale University, Molecular Biophysics & Biochemistry (1984)
MS	Yale University, Molecular Biophysics and Biochemistry (1984)
Fellowship	Brigham and Women`s Hospital
Fellowship	Dana Farber Cancer Institute
Residency	Brigham and Women`s Hospital
HONORS & RECOGNITION
Elected to the Association of American Physicians
AAP (2015)

Addario Foundation Lectureship Award
Bonnie Addario Foundation (2014)

Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research
Dana-Farber/Brigham and Women’s Cancer Center (2014)

Best Doctors, New York Magazine
(2014)

Honorary Professor, University College London Cancer Center
University College London (2012)

Sikand Orator
Yale University (2011)

PROFESSIONAL SERVICE
National Cancer Institute (2012 - Present)
Thoracic Malignancy Steering Committee - National Cancer Institute

Martin Mahoney, MD

Chair of the Department of Clinical Prevention

Roswell Park Comprehensive Cancer Center

Family Medicine, Primary Care, Preventive Medicine, Health Behavior, Lung Cancer, Smoking Cessation, HPV, Vaccination

Chair of the Department of Clinical Prevention, Roswell Park Cancer Institute
Areas of expertise: Family medicine, primary care, preventive medicine, health behavior, lung cancer, smoking cessation, HPV, vaccination

Mary Reid, MSPH

Director of Cancer Screening and Survivorship

Roswell Park Comprehensive Cancer Center

Cancer, Lung Cancer, Cancer Screening, Cancer Detection, Cancer Prevention, Epidemiology

Director of Cancer Screening and Survivorship, Roswell Park Cancer Institute
Areas of expertise: Lung cancer, cancer screening, cancer early detection, epidemiology, cancer prevention

Mark Katlic, M.D.

Chief, Department of Surgery

LifeBridge Health

Lifebridge Health, Sinai Hospital, General Surgery, Thoracic Surgery, geriatric surgery, Esophageal Cancer, Lung Cancer, aging surgeons

Dr. Katlic serves as chief of the Department of Surgery and surgeon-in-chief at Sinai Hospital, is the director of the Sinai Center for Geriatric Surgery and is the founder of The Aging Surgeon Program. While a resident at the Massachusetts General Hospital, he cared for several 100-year old surgical patients and reviewed the records of other elderly patients publishing his results in 1985 in the Journal of the American Medical Association. He is also an author of five textbooks on geriatric surgery. The Aging Surgeon Program is a comprehensive evaluation of the physical and cognitive functions of older surgeons.  

Pandurangan Vijayanand, MD/PhD

William K. Bowes Distinguished Professor

La Jolla Institute for Immunology

Asthma, PrecISE Clinical Center, Lung Cancer, immune fitness, immune profiling, Precision Medicine, genomic tools

Dr. Vijayanand was appointed an Associate Professor in the Division of Vaccine Discovery in 2015. He is the inaugural holder of the William K. Bowes Distinguished Professorship

Dr. Vijayanand received his M.D. from the MGR Medical University in Chennai, India, and completed his residency in Internal Medicine followed by a Pulmonary Fellowship in the United Kingdom. In 2008, he obtained his Ph.D. from the University of Southampton, United Kingdom, where he studied the mechanisms of accumulation and activation of T cells in human asthma. Since then, Dr. Vijayanand has split his time between laboratory research and seeing patients at the University of Southampton, where he currently holds an appointment as an Associate Professor in the School of Medicine. In 2007, he was awarded a prestigious National Career Development Fellowship to undertake translational studies in the epigenetic regulation of the immune cell signaling molecules in human asthma at UC San Francisco, where he was appointed adjunct assistant professor in the Department of Medicine in 2009. Two years later, Vijay joined the La Jolla Institute for Allergy and Immunology as an adjunct assistant professor in the Division of Signaling and Gene Expression.

Amy Moore, Ph.D.

Director of Science & Research,GO2 Foundation for Lung Cancer

GO2 Foundation for Lung Cancer

Cancer, Lung Cancer, Virology, Vaccines

Dr. Amy Moore is the Director of Science and Research at GO2 Foundation. Dr. Amy C. Moore is a PhD-trained virologist and cancer researcher and has spent over a decade working on large statewide and multi-institution initiatives in cancer and vaccines. She currently serves as Director of Science & Research for the GO2 Foundation for Lung Cancer and also works closely with GO2 Foundation's sister organization, the Addario Lung Cancer Medical Institute (ALCMI), to build research capacity in emerging areas of concern to the lung cancer community.  

Because of her virology training and position as a leader in the advocacy community, Dr. Moore has become a highly sought-after expert to discuss the intersection of lung cancer and COVID-19. Since early March, she has participated in over half a dozen panel discussions, webinars, and interviews with leading groups such as IASLC, CURE, US News & World Report to discuss the threat COVID-19 presents to patients with lung cancer and how we can mobilize research to understand this risk. 

Lung Cancer, Cancer Care, Patient Care

Chief Patient Officer at GO2 Foundation for Lung Cancer and has been working in lung cancer non-profit for the past 11 years. She is responsible for all aspects of patient programming, services, engagement, and empowerment along with strategic insight and planning around lung cancer awareness and education.  Through personal history with lung cancer, Bonnie Addario is her mother, she has had hands-on experience as a caregiver as it relates to lung cancer the disease, treatments, the emotional and physical experience along with experience through survivorship. 

She has developed multiple patient education programs and educational publications that have reach in 143 countries around the world. In her role, she directly touches patients, caregivers, physicians, nurses, and industry professionals. She attends scientific meetings specific to lung cancer, has sat on multiple advisory boards and has experience with speaking engagements across the lung cancer community. 

Showing results 1 – 7 of 7

close
0.76429